4CPS-034 Real-world study of trifluridine/tipiracil-bevacizumab in metastatic colorectal cancer
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance Due to the high incidence of this type of cancer in our area we consider it interesting to do this investigation. Aim and Objectives Evaluate the efficacy and safety of: tifluridine/tipiracil (TAS)-bevacizumab in patients with metastatic colorectal cancer (mCRC). Material and Methods Observational, retrospective study including patients with mCRCC treated with TAS-bevacizumab from 1 January 2022 to 30 July 2024. Variables collected: age, sex, ECOG and mutations, previous treatments, adverse events (AEs) and type of response using the electronic medical record DRAGO-AE. Efficacy has been evaluated in terms of progression-free survival (PFS) and overall survival (OS), defined as the time elapsed from the start of treatment to progression (PFS) or death (OS), calculated using the Kaplan-Meier method. Safety was assessed through the recorded treatment-related AEs, measuring their severity according to the Common Terminology Criteria for Adverse Events (CTCAEv4.0) toxicity scale. Descriptive statistical analysis was performed using SPSS-Statistics 22 software. Results 42 patients (29 men,13 women) whose median age was 62.5 (39–85) were included. The initial ECOG was 0–1 in 66.67% and 2 in 33.33%. KRAS mutation was present in 50% and BRAF in 4.77%. Treatment was prescribed as 2nd line in 2.38%, as 3rd line in 80.95% and as 4th line in 16.67%. The end of treatment was because of disease progression in 88.6%, toxicity in 5.7% and discontinuing in 5.7%. 83.33% of the patients presented AEs of any-grade and up to 53,38% of grade 3–4. The median PFS was 4.05 months (95% CI 3.38–4.71) and the median OS was 11.51 months (95% CI 7.57–15.45). The best response obtained during treatment was partial response in 2.38%, stable disease in 23.81%, disease progression in 54.76% and no response in 19.05% (50% exitus and 50% less than 3 cycles of treatment). Conclusion and Relevance The PFS obtained in our study was lower than that described in the SUNLIGHT study (5.6 months), this could be due to a greater number of patients starting treatment with an ECOG=2 in our study. The OS obtained in our study was longer compared to the literature (10.8 months). EAs of any-grade were similar to those described in the literature, but a lower percentage of grade 3–4 events were detected in our study. References and/or Acknowledgements Conflict of Interest No conflict of interest
Authors: F Madriñán González, C Otero Villalustre, E Mateos Egido, AC Rodriguez Negrin, E Gandullo Sanchez, G Avanzini Martinez, V Garcia Navarro, C Espin Martinez, I Ruiz Santos, AM Alamo Medina, D Fernandez Vera
Institution: Hospital Universitario Insular de Gran Canaria
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408376834